Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes. - Wikidata - awgldk - TriplyDB

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q34539983

about

Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes Chronic kidney disease screening methods and its implication for Malaysia: an in depth review Detection of cystatin C biomarker for clinical measurement of renal disease by developed ELISA diagnostic kits Proximal tubule dysfunction is associated with podocyte damage biomarkers nephrin and vascular endothelial growth factor in type 2 diabetes mellitus patients: a cross-sectional study.Serum cystatin C reflects the progress of albuminuria.Urinary biomarkers for early diabetic nephropathy in type 2 diabetic patients Short-Term High Fat Intake Does Not Significantly Alter Markers of Renal Function or Inflammation in Young Male Sprague-Dawley Rats.Diabetes-induced renal injury in rats is attenuated by suramin The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults.Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker.Urinary N-acetyl-β-D-glucosaminidase, an early marker of diabetic kidney disease, might reflect glucose excursion in patients with type 2 diabetes.Reference intervals for serum cystatin C and factors influencing cystatin C levels other than renal function in the elderly.Proteomic biomarkers in kidney disease: issues in development and implementation.The role of novel biomarkers in predicting diabetic nephropathy: a review.Diagnostic Accuracy of Serum Cystatin C for the Evaluation of Renal Dysfunction in Diabetic Patients: A Meta-Analysis.Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as early markers of diabetic nephropathy Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients.New urinary biomarkers for diabetic kidney disease.Interrelationship of βeta-2 microglobulin, blood urea nitrogen and creatinine in streptozotocin-induced diabetes mellitus in rabbits.The relationship between serum fetuin-A, cystatin-C levels, and microalbuminuria in patients with metabolic syndrome.Routine kidney variables, glomerular filtration rate and urinary cystatin C in cats with diabetes mellitus, cats with chronic kidney disease and healthy cats.Evaluation of creatinine-based and cystatin C-based equations for estimation of glomerular filtration rate in type 1 diabetic patients.Serum cystatin C and prediabetes in non-obese US adults.Clinical Predictive Value of Cystatin C in Pediatric Sickle Cell Disease: A Marker of Disease Severity and Subclinical Cardiovascular Dysfunction.Undiagnosed Kidney Injury in Uninsured and Underinsured Diabetic African American Men and Putative Role of Meprin Metalloproteases in Diabetic Nephropathy.BDNF: mRNA expression in urine cells of patients with chronic kidney disease and its role in kidney function

P2860

Q26740305-FD217481-EDE2-4717-BB97-EE493F7298DB Q26744419-F08ADBB9-6F97-4169-868F-DC2C920A372B Q26822369-45F4D773-43BB-43C9-853E-4F4D82933997 Q34672391-1EEF4B8D-B6AE-4848-A84D-E8371F9F653F Q35421414-4456542C-4E2F-4CA1-903A-37EC4AC83892 Q35661440-C9536FA0-34C2-4F3F-B55A-6CF533BCED79 Q35816851-D230D3C0-4AAD-4DE9-9D93-9874D85B34AD Q35817372-4058B34D-516A-4BBA-96AD-22259568A1FF Q36296876-B4DA773B-1964-4650-B7EA-73E8CF0D28D8 Q36621001-5EDE2D5C-0813-4704-9A55-A35AD8CD68FC Q36629471-84C7638C-D749-4F01-8267-30FE06600D3D Q37108425-0F3ECEE7-51C9-4068-B873-0C6088936D91 Q37328089-32893EED-2C5C-443D-ABF9-189DA346C236 Q37500090-53D8DEB2-11E3-40E1-8635-ED22BAFA3112 Q38341211-2BEABFAB-C6F3-4CCB-9EB4-90478283BF84 Q38598929-43E3A1A0-367F-428B-AAA5-B89A6A8E4848 Q39127610-C8C30D4A-852A-44DB-A672-F11E85ECA94E Q39780122-7EF4A087-A4A2-45AC-9558-CEEE50BB70BD Q41585581-782C5261-7419-44BD-A5CC-C594A2B3706F Q41980284-4C84DA63-5161-42FE-95B1-299A6F2381AB Q42918999-5B903F53-0FEB-46BE-8E86-53A553871954 Q43085155-B13CE59D-97B1-4988-B98C-33B6EB7E9170 Q44074438-38A4E90D-FAE5-49B4-8A20-EC772D455E8A Q49034688-AFFB0ABD-BA51-44C2-9019-E43DDFACB2B7 Q50643798-5F6658B5-0AC3-403F-B1C6-FD35382842DF Q51272947-2ADEFE3F-A369-4DC6-9FB2-EBC12919A36B Q51539523-E9B594A4-851E-4CC0-824D-5C1204A27036 Q55006125-316A0D0D-C26A-497E-9EF1-207AC3AE602E Q58724740-7AE59976-F5F3-4590-825B-6E1B472D3F1E

P2860

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

http://www.wikidata.org/entity/Q34539983

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@ast

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@en

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@nl

type

label

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@ast

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@en

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@nl

prefLabel

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@ast

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@en

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@nl

P1433

Q34539983-F453D3DD-B00D-48CD-924B-13CA225F75E9

P1476

Q34539983-43EC8AA8-2F15-49F1-A587-FA638435CAAA

P2093

Q34539983-242AF188-7514-4031-919B-E16BB0AC3521

Q34539983-39A20460-65F3-4DBD-ACBE-70F7C2AD28E0

Q34539983-3AD12A74-9FFE-45A8-ADDB-4A8D5F3FA8A1

Q34539983-5F7E8DA6-4B9C-42EE-9BD6-9C290BF8E5AC

Q34539983-99695170-FA09-4A63-816D-537C0CBF8376

Q34539983-BBA4DBAE-29CE-4D30-8AF9-7CE4FA4F729F

Q34539983-DD4CF707-DF25-4976-9063-E32B3B0AE42D

Q34539983-E24DA0CA-BFA4-4C6E-8A58-5AB6CDEC6D2E

Q34539983-E63185DE-070C-4A36-8952-C4F3A4294056

P2860

Q34539983-0B19AD70-DE24-4E62-AD87-DEB9A10BEDFD

Q34539983-1443CAE7-699B-48B6-8769-847873BCECA3

Q34539983-18A71BEA-C270-4E83-A9A5-0DF158261818

Q34539983-25E7A6B0-354C-4B65-894F-3639583AD795

Q34539983-49E7DFEF-E390-436C-8E3B-14413B5B339A

Q34539983-5933E44F-312D-4894-BC7D-9237452A1EBE

Q34539983-6172A571-E702-454D-AE2C-3A8BF78FDC27

Q34539983-6514251B-4162-4F6F-97BE-2909199281FF

Q34539983-748110E7-4263-49F9-9BE4-C01E340F3AAF

Q34539983-7841D2AB-6F53-4B6A-9B16-D02B5D399429

P304

Q34539983-9A03E02E-4B78-4FDF-B26A-A70DAF56CC74

P31

Q34539983-D2685275-5FBD-4CF3-9A31-CB074A3DEA07

P356

Q34539983-B79ADB6C-1DD6-4E46-9268-ED970544A247

P433

Q34539983-86B62A9D-EBF8-450E-B3F8-9124492C20DE

P478

Q34539983-89E77837-44C8-4F6C-B7DF-4859ACA42F8F

P50

Q34539983-D6C8A57B-D954-42F2-8483-5F68383D2406

P577

Q34539983-CC6C6E8A-DA96-4981-8B41-C3CCD568D330

P5875

Q34539983-442ACD2C-0D53-4145-B27C-9B3AAD41F860

P698

Q34539983-FD96C82A-BC91-4EE3-A3A8-18DE8CED8DF1

P921

Q34539983-1E878833-A923-40DD-9731-F1F996C7881F

Q34539983-E833D07A-B22E-411F-A891-D1412049E206

P932

Q34539983-D13EE689-6C57-4AAE-96FE-2F692DE90D84

P356

JKMS.2011.26.2.258

P1433

Journal of Korean Medical Science

P1476

Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

@en

P2093

Bo Hyun Kim

http://www.w3.org/2001/XMLSchema#string

In Joo Kim

http://www.w3.org/2001/XMLSchema#string

Ji Young Mok

http://www.w3.org/2001/XMLSchema#string

Jung Eun Huh

http://www.w3.org/2001/XMLSchema#string

Mi Ra Kim

http://www.w3.org/2001/XMLSchema#string

Sang Heon Song

http://www.w3.org/2001/XMLSchema#string

Soo Hyoung Lee

http://www.w3.org/2001/XMLSchema#string

Yong Ki Kim

http://www.w3.org/2001/XMLSchema#string

Yun Kyung Jeon

http://www.w3.org/2001/XMLSchema#string

P2860

Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

Serum cystatin C is sensitive to small changes in thyroid function

Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement

Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program

High prevalence of immuno-unreactive intact albumin in urine of diabetic patients.

Serum cystatin C is a potential endogenous marker for the estimation of renal function in male gout patients with renal impairment.

Measurement of kidney function.

Epidemiology of renal involvement in newly-diagnosed middle-aged and elderly diabetic patients. Cross-sectional data from the population-based study "Diabetes Care in General Practice", Denmark.

Markers of diabetic nephropathy.

P304

258-263

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3346/JKMS.2011.26.2.258

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49802789

http://www.w3.org/2001/XMLSchema#string

P698

21286018

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

3031011

http://www.w3.org/2001/XMLSchema#string